AlzBase: an Integrative Database for Gene Dysregulation in Alzheimer’s Disease
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease afflicting over 30 million patients worldwide. The typical symptoms of AD include memory loss and impairment of cognitive function, and currently, there is no available approach to cure the disease. The projected fast increase of the senior population is a growing burden for the international society in terms of both medical cost and patient care. Since the first case examination in1907, amyloid has been associated with the disease named after its pioneer Dr. Alois Alzheimer. A classical histopathological hallmark for AD is the extracellular deposition of amyloid plaques found in the postmortem brain of AD patients, along with the intracellular neurofibrillary tangles (NFT). It is widely believed that amyloid is the cause of all the symptoms and the eventual death of AD patients. This so called “amyloid hypothesis” is dominant in the field of AD research, and a good portion of the work in this field has been devoted to the mechanism and pathological effect of amyloid formation.